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Abstract
Background: Shiga toxin 2 from enterohemorrhagic Escherichia coli is the etiologic agent of bloody diarrhea,
hemolytic uremic syndrome and derived encephalopathies that may result to death in patients. Being a Gram
negative bacterium, lipopolysaccharide is also released. Particularly, the hippocampus has been found affected in
patients intoxicated with Shiga toxin 2. In the current work, the deleterious effects of Shiga toxin 2 and
lipopolysaccharide are investigated in detail in hippocampal cells for the first time in a translational murine
model, providing conclusive evidences on how these toxins may damage in the observed clinic cases.
Methods: Male NIH mice (25 g) were injected intravenously with saline solution, lipopolysaccharide, Shiga
toxin 2 or a combination of Shiga toxin 2 with lipopolysaccharide. Brain water content assay was made to
determine brain edema. Another set of animals were intracardially perfused with a fixative solution and their
brains were subjected to immunofluorescence with lectins to determine the microvasculature profile, and anti-
GFAP, anti-NeuN, anti-MBP and anti-Iba1 to study reactive astrocytes, neuronal damage, myelin dysarrangements and
microglial state respectively. Finally, the Thiobarbituric Acid Reactive Substances Assay was made to determine lipid
peroxidation. In all assays, statistical significance was performed using the One-way analysis of variance followed by
Bonferroni post hoc test.
Results: Systemic sublethal administration of Shiga toxin 2 increased the expressions of astrocytic GFAP and microglial
Iba1, and decreased the expressions of endothelial glycocalyx, NeuN neurons from CA1 pyramidal layer and
oligodendrocytic MBP myelin sheath from the fimbria of the hippocampus. In addition, increased interstitial fluids and
Thiobarbituric Acid Reactive Substances-derived lipid peroxidation were also found. The observed outcomes were
enhanced when sublethal administration of Shiga toxin 2 was co-administered together with lipopolysaccharide.
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Conclusion: Systemic sublethal administration of Shiga toxin 2 produced a deterioration of the cells that integrate the
vascular unit displaying astrocytic and microglial reactive profiles, while edema and lipid peroxidation were also
observed. The contribution of lipopolysaccharide to pathogenicity caused by Shiga toxin 2 resulted to enhance the
observed hippocampal damage.
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Background
Hemolytic uremic syndrome (HUS) is an illness charac-
terized by a triad of events that include nonimmune
haemolytic anaemia, thrombocytopenia and acute renal
failure caused by Shiga toxin 2 (Stx2) from enterohe-
morrhagic Escherichia coli (EHEC). Patients may initially
develop bloody diarrhea when EHEC succeeds to
colonize the gastrointestinal tract. Once Stx2 reaches the
circulation it may target endothelial, kidney and/or brain
cells through the Stx2 globotriaosylceramide receptor
(Gb3) causing cytotoxicity [1]. Neurological impairment
frequently occurs and is associated with a worse prog-
nostic [2]. Besides Stx2 pathogenicity, lipopolysaccharide
(LPS) is another virulence factor that is also released
form EHEC [3], for being a Gram negative bacteria. The
action of LPS has been described as an enhancer of the
deleterious effects of Stx2 in different cells [4] and or-
gans such as the brain [4, 5].
Particularly in Argentina, post diarrheal HUS is en-
demic and possesses the highest rate of pediatric cases
in the planet. 400 cases are reported annually with an in-
cidence of 10 to 17 cases per 100,000 children under 5
years old, and among them lethality was reported be-
tween 1 and 4% [6]. In addition, a high percent of the
pediatric patients with HUS develop central nervous sys-
tem (CNS) dysfunctions [2]. As the grade of severity in
HUS cases is usually associated with neurological dys-
functions, the mortality rate rises significantly between 2
to 3-folds when the CNS is involved [7]. Moreover, it
has been reported that about 9 to 15% showed neuro-
logical symptoms before the onset of HUS [7].
Although reports on cognitive dysfunctions have been
reported in HUS patients, research in brain cognitive
areas such as the hippocampus has been scarcely de-
scribed. As mentioned, a case of cognitive dysfunctions
in HUS patients occurred during a large outbreak of
diarrhea-associated HUS in Germany 2011 [8]. The re-
sponsible was an unusual enteroaggregative Shiga
toxin-producing Escherichia coli (STEC) O104:H4. 2987
adults were registered with gastrointestinal infections.
22% of them underwent HUS, while more than a half of
them acquired neurologic alterations and about 58% of
those with neurologic involvement suffered from cogni-
tive dysfunction, like trouble finding words, severe alter-
ation of consciousness or late memory decline [9]. In
addition, other reports of Stx2-derived encephalopathy
observed alteration of memory and consciousness, sei-
zures and coma [10]. As known, the hippocampus is in-
volved in cognitive functions including memory
formation [11]. Functionally, the hippocampus is one of
the brain areas found vulnerable to the deleterious ac-
tions of Stx2 [8]. Neurons from the hippocampal CA1
region are mainly involved in memory tasks. Among
them long-term potentiation and spatial learning is es-
sentially controlled by these neurons [12]. As Stx2
caused memory alterations including orientation deficits
in patients [13], and as we demonstrated the presence of
the Stx2-Gb3 cell receptor in neurons from the CA1
layer [14], we prompted us to study particularly the cel-
lular events that occurred in such and surroundings
layers of the hippocampus. In the current work, the
deleterious effects of Stx2 and LPS are investigated in
detail in hippocampal cells for the first time, providing
conclusive evidences on how these toxins may damage
in the observed clinic cases.
Methods
Animals
NIH male Swiss mice of approximately 25 g (30 days,
housed under 12 h-light/12 h-dark cycles) were divided
into 4 different groups according to their intravenous (i.v.)
treatment: control (saline solution), LPS (800 ng, E. coli
055:B5, Sigma, St. Louis, MO, USA), Stx2 (0.5 ng or 1 ng,
Phoenix Laboratory, Tufts Medical Center, Boston, MA,
USA) and Stx2 + LPS (1 ng and 800 ng ± respectively). The
total amount of i.v. solution injected was 100 μl per mouse
and the Stx2 dose was about 60% of the LD50 (1.6 ng per
mice). Food and water were provided ad libitum and the
experimental protocols and euthanasia procedures were
reviewed and approved by the Institutional Animal Care
and Use Committee of the School of Medicine of Univer-
sidad de Buenos Aires, Argentina (Resolution N° 046/
2017). All the procedures were performed in accordance
with the EEC guidelines for care and use of experimental
animals (EEC Council 86/609).
Brain water content assay
The dry/wet weight method was applied to the brain of
mice divided in groups according to their i.v. treatments
as described above. The mice (n = 10) were sacrificed at
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6, 12, 24 or 48 h post-i.v. treatment. The entire brain
was used for this assay and they were weighted on a pre-
cision balance of 10 μg accuracy (Acculab ALC-110.4,
Brooklyn, NY, USA) to obtain their wet weight. Then,
they were dried in an incubator at 56 °C for 6 days to ob-
tain their dry weight. The water content was determined
from the difference between the wet weight and dry
weight, according to Testylier et al. (2007) [18].
Histo and immunofluorescence assay
Mice (n = 4 for each treatment) were anesthetized with
pentobarbital (100 mg/kg) and intracardiacally perfused
with paraformaldehyde 4% diluted in phosphate buffer
saline (PBS) 0.1M, pH 7.4; at 2, 4, 7 and 20 days. Day 0
was set as the day of the i.v. treatment. The brains were
removed from the skulls and post-fixed overnight at 4 °C
with the same described fixative solution, then daily
cryopreserved with increasing concentrations of sucrose
diluted in PBS (10, 20 and 30%). Brain sections of 20 μm
were cut in a cryostat. The brains slices were storage at
− 20 °C in a cryopreservant solution (50% PBS, 30%
ethylene glycol and 20% glycerol) until the day of histo
and/or immunofluorescence assay.
The histofluorescence assay to detect the glycocalyx
microvasculature was made with 10 μg/ml of biotinyl-
ated lectin from Lycopersicon esculentum (Sigma, St.
Louis, MO, USA). Brain slices were first washed several
times with PBS 10 mM to be incubated overnight with
lectin at 4 °C. The slices were then washed several times
with PBS 10 mM and incubated overnight with streptavi-
dine Alexa Fluor 488 (Invitrogen Molecular Probes,
Carlsbad, California, USA) at 4 °C followed by several
washed in PBS to be mounted on slides for epifluores-
cence (Olympus BX50, Miami, Fl, USA) and confocal
microscope (Olympus FV1000, Miami, Fl, USA) studies.
For the immunofluorescence assay, after several rinses
with PBS 10mM, brain slices were incubated with 10%
fetal goat serum blocking solution in PBS 10mM
(Sigma, St. Louis, MO, USA) and 1% Triton X-100
(Sigma, St. Louis, MO, USA) for 1 h. The sections were
immediately incubated with the following primary anti-
body (with Triton X-100 at 0,3%): rabbit anti-GFAP
(1:500 - Dako, 225 Glostrup, Denmark), mouse
anti-NeuN (1:250 - Millipore, Temecula, CA, USA),
rabbit anti-MBP (1:500 - Dako, Glostrup, Denmark),
goat anti-Iba1 (1:250 - Millipore, Temecula, Ca, USA) and
rat anti-Gb3 (CD77, 1:250 - Serotec, Kidington, UK) over-
night at 4 °C to identify astrocytes, neurons, oligodendro-
cytes, microglial cells and the Stx2 Gb3 receptor
respectively. Once the sections were rinsed several times
with PBS 10mM they were incubated with their respective
secondary antibodies (with Triton X-100 at 0,3%): goat
anti-rabbit Alexa Fluor 555 (1:500 - Invitrogen Molecular
Probes, Carlsbad, California, USA), goat anti-mouse Alexa
Fluor 555 (1:500 - Amersham, GE, Piscataway, NJ, USA),
donkey anti-goat Alexa Fluor 555 (1:500 - Millipore, Te-
mecula, Ca, USA) and goat anti-rat FITC (Jackson
Immuno Research, West Grove, PA, USA) overnight at 4 °
C. Finally, all hippocampal brain slices were incubated
with Hoechst 33342 (1:500 - Sigma, St. Louis, MO, USA)
for 15min at room temperature to show the nuclei of
brain cells. Negative controls were made by omitting the
primary antibody. The hippocampal CA1 area was ob-
served with an Olympus BX50 epifluorescence micro-
scope provided with a Cool-Snap digital camera and
Olympus FV1000 confocal. Micrographs were obtained
from CA1 hippocampal field, (− 1.70 and − 1.82mm from
bregma). Analysis of lectin histofluorescence, GFAP and
Iba1 immunofluorescences were made in hippocampal
CA1 stratum radiatum (Rad), while immunofluorescence
to neuronal NeuN was analyzed in the CA1 pyramidal
layer (Py). Finally, immunofluorescence to MBP was ob-
served in the hippocampal fimbria (fi). The obtained mi-
crographs were analyzed with the Fiji ImageJ software
(NIH, MD, USA). GFAP and Iba1 expression levels were
measured as the integral optical density (IOD) per cell,
while histofluorescence to lectin and MBP expression
levels were measured as total IOD of each micrograph.
For this purpose, all images were opened on Fiji Ima-
geJ, the color channels were splitted and the one with
the specific color was selected. In order to select only
the immunopositive cells, the threshold tool was
employed and the IOD was measured with the Analy-
ze>Measure tool, and the “mean” was selected. The cri-
teria to determine endothelial damage on lectin images
were the number of lectin positive particles and the area
occupied by the microvessels. For this purpose, the im-
ages were calibrated with a pre-set scale bar, the straight
tool was employed to set a line of the same size of the
scale bar and using the set measurements the length of
the line was calibrated. After that, the color channels
were splitted, the green color was selected and the same
steps to analyze the IOD were done, with the difference
that in this case, the measurements of “area” and “count”
were selected. Finally, the measurement in 3 different
places of the Py was made to determine neuronal dam-
age in the Py layer. For this purpose, the scale bar was
set as it was described before, and the thickness of the
pyramidal layer was measured using the straight tool.
Thiobarbituric acid reactive substances assay
The malondialdehyde (MDA) content in hippocampus
(n = 4) was evaluated as thiobarbituric acid reactive sub-
stances (TBARS) by a fluorometric assay with modifica-
tions at 12 h and 24 h following toxin treatments.
Butylhydroxytoluene (4% w/v in ethanol) was used to
prevent non-physiological TBARS formation during the
sample processing [15]. Results are expressed as pmoles
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of MDA per mg of protein. The MDA standard was pre-
pared from 1,1,3,3,-tetramethoxypropane.
Statistical analysis
The data are presented as mean ± SEM. In all assays, the
statistical significance were performed using the
One-way analysis of variance (ANOVA) followed by
Bonferroni post hoc test (GraphPad Prism 4, GraphPad
Software Inc.) between the 4 i.v. treatments (control,
LPS, Stx2 and Stx2 + LPS). The criterion for significance
was p < 0.05 for all the experiments.
Results
Water content of murine brains was increased following
systemic administration of a sublethal dose of Stx2
In previous works sub-lethal dose of Stx2 was deter-
mined and administered to a characterized murine
model of encephalopathy, to mimic and to unravel the
cell mechanisms that may occur beyond the clinical
signs observed in patients suffering from HUS [16]. Sys-
temic administration of Stx2 provoked disarrangements
on striatal blood brain barrier (BBB) cell components ev-
idenced by immunofluorescence techniques [17] and
perivascular edema was confirmed by electron micros-
copy [16]. In the present work, the brain water content
was assessed following a characterized protocol [18] to
determine whether the observed increase in reactive as-
trocytes (Fig. 3) and lectin bound to glycocalyx mole-
cules derived to a decrease in the area occupied by these
molecules in the BBB (Fig. 4) and whether these events
correlated with the brain edema. As observed, a signifi-
cant rise in water content was detected after 12 h of Stx2
administration. This rise was kept at 48 h (Fig. 1).
Stx2 increased the expression levels of glial fibrilar acidic
protein (GFAP) in the murine brain hippocampus in a
dose dependent manner
GFAP is a cytoskeletal protein used as a specific marker
to identify astrocytes in a reactive state because of a wide
variety of brain injuries [19]. Two different sublethal
doses of Stx2 were intravenously (i.v.) administered to
determine whether deleterious effects of the toxin in
brain cells may occur in a dose dependent manner (0.5
and 1 ng) and the day 4 was chosen to observe these ef-
fects. In our murine model, sublethal administration of
Stx2 maximally induced reactive astrocytes and other
events in the motor cortex and striatum at day 4 [5, 17].
At this context, the day 4 was initially chosen in
order to establish the amount of Stx2 to be used in
this work, and latter, a time curve was designed in
order to determine the time Stx2 maximally induce
reactive astrocytes but particularly in the murine hip-
pocampal area CA1.
A basal immuno-expression of GFAP was observed in
astrocytes located in the hippocampal CA1 stratum
radiatum (Fig. 2I) from control treated mice (Fig. 2a-b).
In contrast to this, i.v. administration of 0.5 ng of Stx2
resulted to significantly increase GFAP immunoexpres-
sion (Fig. 2c-d). Moreover, i.v. administration of 1 ng of
Stx2 (Fig. 2e-f ) significantly increased even more react-
ive astrocytes (Fig. 2h). According to the preceding re-
sults, 1 ng was selected to study the deleterious effects of
this toxin in the hippocampus. No immunofluorescence
was observed in negative controls by omitting primary
antibody (Fig. 2g).
Systemic administration of Stx2 produced reactive
astrocytes and the combination of this toxin with LPS
resulted to enhance this effect
GFAP immunoexpression was measured in hippocampal
stratum radiatum of the CA1 area (Fig. 3k) to determine
whether systemic administration of Stx2 and/or LPS
caused reactive astrocytes. According to this, maximal
expression of GFAP was observed in all mice treated
with both toxins at day 2 compared with the same treat-
ments of the other 3 days (4, 7 and 20 days) as shown in
Fig. 3. Co-administration of Stx2 + LPS at day 2 yielded
maximal astrocyte reactivity in comparison with control,
LPS and Stx2 treated mice (Fig. 3a-h). Also, reactive as-
trocytes measured by GFAP immunoexpression were
significantly increased after 4 and 7 days in Stx2, LPS
and Stx2 + LPS mice groups in comparison to the con-
trol one. Nevertheless, non significant reactive astrocytes
were observed in the expression level of GFAP after 20
days except Stx2 + LPS treated one (Fig. 3j). No im-
munofluorescence was observed in negative controls by
omitting primary antibody (Fig. 3i).
Fig. 1 Stx2 increases the water content in murine brains. The
letters above each column (a, b, c) mean significant differences.
Data were analyzed by One-way ANOVA, Bonferroni’s post hoc
test, p < 0.05, n = 10
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Stx2 decreased the area occupied by lectin-bound to
glycocalyx microvessels and the co-administration with
LPS enhanced this effect
Lectins (Lycopersicum esculentum) are non-immune pro-
teins that bind with high affinity to specific N-acetyl-
D-glucosamine and poly-N-acetyl lactosamine sugar resi-
dues of endothelial plasma membrane glycocalyx [20].
Thus, they are useful markers to study the microvascula-
ture profile in the stratum radiatum of the CA1 hippo-
campal layer (Fig. 4l). Control treated mice (Fig. 4a-b)
showed continuous lectin fluorescence binding through-
out all microvessels though resulting well preserved, with
continuous and defined edges since the 2 days of treat-
ment and persisting at 4, 7 and 20 days of observation
(Fig. 4c-h). After 2 days of treatment, the number of
microvessels was significantly increased in the LPS, Stx2
and Stx2 + LPS treated mice in comparison to the control
one (Fig. 4j). As observed, the maximal number of micro-
vessels expressing the glycocalyx was observed after 2 days
in Stx2 + LPS treated hippocampal brain mice. However,
the number of these glycocalyx molecules from the differ-
ent toxin treatments tended in 20 days to match those
from the control group (Fig. 4j). According to the area oc-
cupied by endothelial glycocalyx, the control treated mice
occupied a larger area per observed field than those from
the toxins treated mice (Fig. 4k) at day 2, becoming this
area minimal when mice were co-treated with Stx2 + LPS
(Fig. 4g-h, k). No immunofluorescence was observed in
negative controls by omitting primary antibody (Fig. 4i).
The expression of neuronal NeuN was decreased in
hippocampal CA1 pyramidal layer (Py) following the
administration of Stx2
With the purpose to measure the thickness of the pyram-
idal layer of neurons from the hippocampus CA1 area
(Fig. 5l) an antibody anti-NeuN was employed. NeuN is a
splicing alternative factor expressed in neurons and is often
used as a neuronal nuclear marker [21, 22]. After 2 days of
treatment, the toxins decreased the expression of NeuN
that resulted in the reduction of the thickness of Py in com-
parison with the control. Py was maximally reduced in
Stx2 + LPS treated mice (Fig. 5a-h, k). After 4 days of treat-
ment, a decrease in the expression of NeuN was observed
in the mice treated with the toxins but in a lesser extent
Fig. 2 Stx2 produces reactive astrocytes in a dose dependent manner. Control (a-b); 0.5 ng of Stx2 (c-d); 1 ng of Stx2 (e-f) after 4 days of
treatment. Immunofluorescence using an anti-GFAP antibody (a, c, e). Merge images between anti-GFAP immunofluorescence and Hoechst
histofluorescence (b, d, f). Negative controls by omitting primary antibody (g). Quantification of integral optical density (IOD) from reactive
astrocytes (h). The drawn square shows the area analyzed which corresponds to the hippocampal CA1 Rad area (i). Different letters (a, b, c) above
the columns indicate significant differences between each dose (h). Scale bar in Fig. G applies to all micrographs. Data were analyzed by One-way
ANOVA, Bonferroni’s post hoc test, p < 0.05, n = 4
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than in those observed at day 2. After 20 days of toxin treat-
ments no significant differences were found in the expres-
sion of NeuN and in the thickness of Py (Fig. 5k). Finally,
Py neurons immunolabeled with the anti-NeuN antibody
were also immunolabeled with an anti-Gb3 antibody
(Fig. 5i), indicating that these neurons expressed the Stx2
receptor. No immunofluorescence was observed in negative
controls by omitting both antibodies (Fig. 5j).
The expression of oligodendrocytic MBP myelin protein
was decreased following Stx2 administration
In the current murine model, we have previously shown
by electron microscopy, among other features, that Stx2
produced disorganized oligodendrocytic myelin sheaths
[16]. In the present work, we wanted to determine
whether these disorganized myelin sheaths involved also
differences in the expression level of myelin basic pro-
tein (MBP), a molecule present in mature myelin oligo-
dendrocytes involved in the maturation of the nerves
[23], also employed as an oligodrendocytic marker of
myelin formation. In the hippocampus, MBP is located
in axonal projections of the fornix/fimbria (Fig. 6k). Fol-
lowing Stx2 administration, the expression of MBP sig-
nificantly decreased after 2 and 4 days (Fig. 6e, f, j). After
7 days the expression of MBP tended to be compensated
in comparison to the control, but significant differences
Fig. 3 Stx2 and Stx2 + LPS produce reactive astrocytes. Representative micrographs of murine brain hippocampuses after 2 days of control, LPS,
Stx2 or Stx2 + LPS treatments (A-H). Immunofluorescence using an anti-GFAP antibody (a, c, e, g). Merge images between anti-GFAP
immunofluorescence and Hoechst histofluorescence (b, d, f, h, k). Control-treated mice (a-b); LPS-treated mice (c-d); Stx2-treated mice (e-f) and
co-administration with Stx2 + LPS-treated mice (g-h). Negative control by omitting a primary antibody (i). Expression levels of GFAP from reactive
astrocytes under all treatments at 2, 4, 7, and 20 days (j). A low magnification micrograph shows hippocampal layers: oriens layer (Or), pyramidal
layer (Py), stratum radiatum (Rad) and the area analyzed in this study was Rad from the CA1 hippocampal area (the drawn square shows the area
analyzed) (k). Different letters (a, b, c, d) above the columns indicate a significant difference between the 4 different i.v.-treated groups (j). The
scale bar in Fig. I applies to all micrographs. Data were analyzed by One-way ANOVA, Bonferroni’s post hoc test, p < 0.05, n = 4
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between different groups was still observed (Fig. 6j). LPS
administration also decreased the expression of MBP in
the same days compared with control, however in a
lesser extent than Stx2 (Fig. 6c, d, j). Finally, minimal ex-
pression of MBP was found following the administration
of Stx2 + LPS after 4 days (Fig. 6g, h, j). No immunofluor-
escence was observed in negative controls by omitting pri-
mary antibody (Fig. 6i).
Stx2 produced microglial reactivity and co-administration
of Stx2 with LPS increased this event
The ionized calcium-binding adaptor molecule 1 protein
(Iba1) is a microglia/macrophage-specific calcium-binding
protein commonly used to identify microglial activation
[24]. Therefore, an anti-Iba1 antibody was used to detect
microglia activation by Stx2 and/or LPS in mouse hippo-
campal stratum radiatum (Fig. 7k). Activated microglial
cells were defined by the expression levels of the micro-
glial marker Iba1 (Fig. 7j). Maximal increase in the expres-
sion of Iba1 was found in activated microglia after 2 days
of co-treatment with Stx2 + LPS, being the treatment with
Stx2 + LPS the highest value compared with controls
(Fig. 7a-h). Also, significant microglial activation was
assessed at day 4 in mice treated with LPS, Stx2 and Stx2
+ LPS in comparison to controls, but in a lesser extent
compared with day 2 (Fig. 7j). At day 7, only mice treated
Fig. 4 Microvasculature profile of the mouse hippocampus treated with Stx2 or Stx2 + LPS. Control (a-b), LPS (c-d), Stx2 (e-f) and Stx2 + LPS (g-h)
after 2 days of treatments. Representative lectin histofluorescence micrographs (a, c, e, g). Merge micrographs between lectin and Hoechst
histofluorescences (b, d, f, h, l). Number of glycocalyx positive particles at 2, 4, 7 and 20 days (j). Area occupied by glycocalyx in microvessels from
different treatments at 2, 4, 7 and 20 days (k). The area analyzed in this study was Rad from the CA1 hippocampal area (drawn rectangle) (l).
Negative control by omitting a primary antibody (i). Different letters (a, b, c, d) above the columns indicate a significant difference between the 4
different i.v.-treated groups (j-k). The arrows indicate the areas where the lectin-binding glycocalix was not express by endothelial cells (g). The
scale bar in Fig. I applies to all micrographs. Data were analyzed by One-way ANOVA, Bonferroni’s post hoc test, p < 0.05, n = 4
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with Stx2 + LPS displayed significant microglial activation
compared to controls (Fig. 7j). Finally, after 20 days, all
treated mice with either LPS, Stx2 or Stx2 + LPS showed
no significant differences in the expression levels of Iba1
denoting no microglial reactivity, returning to control
values. No immunofluorescence was observed in negative
controls by omitting primary antibody (Fig. 7i).
Lipid peroxidation was determined following Stx2 and
Stx2 together with LPS administration
TBARS (thiobarbituric acid reactive substances) assay was
determined to evaluate the lipid status in cell membranes
of murine hippocampuses (Fig. 8). Malondialdehyde
(MDA) content was measured as a marker of lipid peroxi-
dation. After 12 h and 24 h of treatments no significant
difference were observed between MDA production in
control and LPS treatments. However, MDA content was
found significantly increased in Stx2 treated mice respect
LPS and control ones, while the treatment with Stx2 +
LPS yielded the maximal production of MDA in compari-
son to all treatments at these periods of time (Fig. 8).
Discussion
The present results show for the first time the deleteri-
ous effects of systemic sub-lethal Stx2 in the hippocam-
pus of murine brains at the cell level. Increased water
content in the brain was determined 12 h until 48 h fol-
lowing Stx2 treatment. One possibility that may explain
the observed increased in water content is the reported
decrease in the expression of aquaporins involved in
fluid elimination from the brain and the increased per-
meability of the BBB leading to brain edema [25]. Stx2
provoked astrocyte reactivity in a dose dependent man-
ner peaking at 48 h. This might have aggravated the ob-
served BBB disarrangement. According with this
observation, Stx2 and co-treatment of Stx2 with LPS led
to the alteration of the endothelium evidenced by dis-
continuity of the endothelial glycocalyx which compro-
mised the BBB integrity. As intact glycocalyx is
necessary for the maintenance of normal vascular func-
tion [26] its discontinuity was reflected as a decrease in
the expression of the glycocalyx [27]. This disorder (in-
creased BBB permeability) induced by Stx2 was already
Fig. 5 The expression of NeuN from the CA1 Py layer is reduced following toxins treatments. NeuN immunofluorescence (a, c, e, g) and merge
images between NeuN immunofluorescence and Hoechst histofluorescence (b, d, f, h, l). Control (a-b), LPS (c-d), Stx2 (e-f) and Stx2 + LPS (g-h)
corresponding to the treatments of day 2. Merge images from a representative hippocampal control section between Gb3, GFAP immunofluorescences
and Hoechst histofluorescence (i). Negative control by omitting primary antibody (j). NeuN expression in CA1 Py layer of all treatments at 2, 4, 7 and 20
days (k). Different letters (a, b, c, d) above the columns indicate significant differences between each column (k). The drawn rectangle was the area
analyzed (l). The scale bar in Fig. J applies to all micrographs. Data were analyzed by One-way ANOVA, Bonferroni’s post hoc test, p< 0.05, n= 4
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demonstrated by our group in the murine brain and
cerebellum by using the Evans Blue staining [5, 28]. BBB
alteration seemed to impact on CA1 hippocampal neur-
onal status; as the expression of NeuN was reduced, the
thickness of the pyramidal layer was decreased in com-
parison to controls. Two possibilities may explain the
decreased of the thickness in this layer as a consequence
of toxin treatments. One possibility is the loss of fluid
content in neurons and consequently the reduction of
neuronal somatic size, while this was totally reversed
after 20 days following the toxins treatments. Neuronal
loss of fluid content has been previously reported by us
in the murine striatum following the same characterized
murine model of HUS-encephalopathy [16]. Alterna-
tively, a temporal inhibition in the expressions of NeuN
and MBP might have occurred, which recovered after
20 days [29]. These events could occur in those
STEC-HUS patients that resolved acute symptoms from
neurological disorders [30]. To confirm this, further ex-
periments would be conducted that escapes the current
aim of the present work. In accordance to this, the ob-
served lipid peroxidation may contribute to the reduc-
tion in the expression of neuronal NeuN from pyramidal
CA1 layer. The assessment of lipid peroxidation has
been determined in a model of renal failure following
intravenous administration of Stx2 [31]. Then, it was not
Fig. 6 Stx2 and Stx2 + LPS damage the myelin sheath. Micrographs of mouse brain hippocampus after 4 days of treatment with control, LPS, Stx2
or Stx2 + LPS (A-H). Immunofluorescence using an anti-MBP antibody (a, c, e, g). Merge images between anti-MBP immunofluorescence and
Hoechst histofluorescence (b, d, f, h, k). Control-treated mice (a-b); LPS-treated mice (c-d); Stx2-treated mice (e-f) and Stx2 + LPS-treated mice (g-
h). Negative control by omitting a primary antibody (i). MBP expression under all treatments at 2, 4, 7 and 20 days (j). Different letters (a, b, c, d)
above the columns indicate a significant difference between each column (j). A low magnification micrograph shows different areas of the
mouse brain: corpus callosum (cc); dorsal 3rd ventricle (D3V); cingulate cortex (cg); fields of the hippocampus (CA1, CA2, CA3 and DG); lateral
ventricle (LV) and fimbria of the hippocampus (Fi); the drawn square in the Fi was the area analyzed (k). The scale bar in Fig. I applies to all
micrographs. Data were analyzed by One-way ANOVA, Bonferroni’s post hoc test, p < 0.05, n = 4
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Fig. 7 Stx2 and Stx2 + LPS treatments increased the expression level of Iba1. Control (a-b), LPS (c-d), Stx2 (e-f) and Stx2 + LPS (g-h) after 2 days of
treatments. Representative micrographs of anti-Iba1 immunofluorescence (a, c, e, g). Merge micrographs between anti-Iba1 immunofluorescence
and Hoechst histofluorescence (b, d, f, h, k). Negative control by omitting a primary antibody (i). Iba1 expression levels at 2, 4, 7 and 20 days (j).
The area analyzed was the drawn square in Rad area from the CA1 hippocampus (k). Different letters (a, b, c, d) above the columns indicate
significant difference between different groups (j). The scale bar in fig. I applies to all micrographs. Data were analyzed by One-way ANOVA,
Bonferroni’s post hoc test, p < 0.05, n = 4
Fig. 8 TBARS measurement in the murine hippocampus. The content of lipid peroxidation was measured by Thiobarbituric Acid Reactive
Substances (TBARS) after 12 h and 24 h. Data were analyzed by One-way ANOVA, Bonferroni’s post hoc test, p < 0.05, n = 4
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surprised to detect lipid peroxidation in the hippocam-
pus which may lead to cell death.
Stx2 may target neurons through Gb3 receptor. The
presence of this receptor was previously immunoloca-
lized in neurons, but not in astrocytes [14, 32]. Then the
possibility that Stx2 may exert a direct neurodegenera-
tive action through Gb3 is highly probable. How Stx2
may target astrocytes then? It was found that Stx2 re-
leases high amounts of glutamate from neurons [32].
This event generates excitotoxicity promoving astrocyte
reactivity, an event by which an inflammatory process
occurs [33]. Then it could be inferred from the previous
description that Stx2 influences astrocytes indirectly. Al-
ternatively, Stx2 may target directly astrocytes not
through Gb3 but by the presence of the TLR4 receptor.
It has been reported that Stx2 activates neutrophils and
release cytokines when it binds the TLR4 receptor [34].
Then, astrocytes may respond in a similar way as neu-
trophils respond to Stx2.
Microglial reactivity was observed 2 days after toxin
treatments. These cells might have contributed to the ob-
served deleterious effects in the CA1 layer. Microglial acti-
vation possesses phagocytic properties, but produces and
releases detrimental pro-inflammatory cytokines [35]. In
addition, reduction of oligodendrocityc MBP may have
obeyed as a consequence of the observed astrocytic and
microglial activations, and/or neuronal disarrangements.
A previous work showed that incubation of Stx2 in cul-
tured oligodendrocytes had no harming effects [36]; how-
ever, oligodendrocytes were damaged in a brain context.
Then, communication between neurons and oligodendro-
cytes appears to be essential for healthy myelin [36]. It has
been reported that when oligodendrocytes extend its pro-
cesses they are able to myelinate axons, keep axonal integ-
rity, support axonal metabolism and neuronal survival
[37]. On the other hand, microglial cells may damage oli-
godendrocytes and/or the myelin sheath as they express
pro-inflammatory cytokines such as TNFα and/or IL-1β
[38, 39]. In addition, they produce ROS and NO radicals,
both important sources of oxidative damage observed dur-
ing the pathogenesis of demyelinating diseases [40]. Lipid
peroxidation may occur in oligodendrocytes. In summary,
Stx2 reaches the brain affecting the BBB. Edema and lipid
oxidation were earlier events. Microglial and/or astrocyte
cells could be potential local inducers of the observed lipid
damage. According to this, these cells were maximally ac-
tivated at 2 days following toxin administration which co-
incided with the observed neuronal alteration (as the
thickness of the CA1 pyramidal hippocampal layer de-
creased). A late event was observed in oligodendrocytic
myelin sheath reduction that occurred 4 days following
toxins administrations. Further studies should be carried
out in order to determine possible mechanisms of cell
plasticity observed at 20 days.
Conclusion
Stx2 damaged the neurovascular unit of the hippocam-
pal area CA1, producing interstitial edema and a de-
crease in the profile of endothelial-glycocalyx expression
that correlated with the disruption of the BBB. Addition-
ally, Stx2 produced astrocytic and microglial cell reactiv-
ity and lipid peroxidation. Neurons and oligodendrocytic
myelin sheath were found maximally damaged at day 2
and day 4 respectively following Stx2 administration.
Co-administration of LPS enhanced the deleterious ef-
fect of Stx2 in the hippocampal area CA1. Then, LPS
should be taken in consideration in HUS-derived en-
cephalopathy models. The detrimental effects of these
toxins were reversed at day 20. The present work could
significantly shed light in the understanding of cell
mechanisms that lead to hippocampal damage following
sub-lethal administration of Stx2 and LPS. This know-
ledge could impact in the search for alternative treat-
ments in the hippocampus of patients intoxicated with
STEC strains.
Abbreviations
CNS: Central Nervous System; EHEC: Enterohemorrhagic Escherichia coli;
Gb3: Globotriaosylceramide receptor; GFAP: Glial Fibrillary Acidic Protein;
HUS: Hemolytic Uremic Syndrome; i.v.: intravenous; Iba1: Ionized Calcium-Binding
Adapter Molecule 1; IOD: Integral Optical Density; LPS: Lipopolysaccharide;
MBP: Myelin Basic Protein; MDA: Malondialdehyde; NeuN: Neuronal Nuclear
Antigen; STEC: Shiga toxin-producing Escherichia coli; Stx2: Shiga toxin 2;
TBARS: Thiobarbituric Acid Reactive Substances
Acknowledgments
We wish to thank Dr. Victoria Rosato-Siri for her invaluable advice and
support in the preparation of this work.
Funding
This work was supported by Agencia Nacional de Promoción Científica y
Tecnológica (ANPCyT) (PICT-2016-1175) and Universidad de Buenos Aires
(UBACyT) (20020160100135BA), Argentina.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
Conceived of the experiment: JG, CB, AP. Conducted the experiment: CB, AP,
VC, DA, AC, PG. Analyzed the data: CB, VC, AP, DA, AC, PG. Wrote the manuscript:
AP, CB, PE, JG. All authors read and approved the final manuscript.
Ethics approval
Experimental protocols and euthanasia procedures were reviewed and
approved by the Institutional Animal Care and Use Committee of the School
of Medicine of Universidad de Buenos Aires, Argentina (Resolution N° 046/
2017). All the procedures were performed in accordance with the EEC




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Berdasco et al. Journal of Biomedical Science           (2019) 26:16 Page 11 of 12
Author details
1Universidad de Buenos Aires, Consejo Nacional de Investigaciones
Científicas y Técnicas (CONICET), Instituto de Fisiología y Biofísica ‘‘Houssay”
(IFIBIO), Laboratorio de Neurofisiopatología, Facultad de Medicina, Paraguay
2155 piso 7, 1121 Buenos Aires, Argentina. 2Universidad de Buenos Aires,
CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL), Facultad de
Farmacia y Bioquímica, Buenos Aires, Argentina. 3Centro Nacional de Control
de Calidad de Biológicos (CNCCB), ANLIS “Dr. Carlos G. Malbrán”, Ciudad
Autónoma de Buenos Aires, Argentina. 4Universidad de Buenos Aires,
Facultad de Farmacia y Bioquímica, Departamento de Química Analítica y
Fisicoquímica, Cátedra de Química General e Inorgánica, Buenos Aires,
Argentina.
Received: 14 September 2018 Accepted: 1 February 2019
References
1. Lengeling A, Mahajan A, Gally DL. Bacteriophages as pathogens and
immune modulators? MBio. 2013;4(6):e00868–13.
2. Nathanson S, Kwon T, Elmaleh M, Charbit M, Launay EA, Harambat J, et al.
Acute neurological involvement in diarrhea-associated hemolytic uremic
syndrome. Clin J Am Soc Nephrol. 2010;5(7):1218–28.
3. Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J
Intern Med. 2017;281(2):123–48.
4. Louise CB, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome:
combined cytotoxic effects of Shiga toxin and lipopolysaccharide
(endotoxin) on human vascular endothelial cells in vitro. Infect Immun.
1992;60(4):1536–43.
5. Pinto A, Cangelosi A, Geoghegan PA, Goldstein J. Dexamethasone prevents
motor deficits and neurovascular damage produced by Shiga toxin 2 and
lipopolysaccharide in the mouse striatum. Neuroscience. 2017;344:25–38.
6. Rivas M, Chinen I, Miliwebsky E, Masana M. Risk Factors for Shiga Toxin-
Producing Escherichia coli-Associated Human Diseases. Microbiol Spectr.
2014;2:5.
7. Obata F. Influence of Escherichia coli Shiga toxin on the mammalian central
nervous system. Adv Appl Microbiol. 2010;71:1–19.
8. Magnus T, Rother J, Simova O, Meier-Cillien M, Repenthin J, Moller F, et al.
The neurological syndrome in adults during the 2011 northern German E.
Coli serotype O104:H4 outbreak. Brain. 2012 Jun;135(Pt 6):1850–9.
9. Schuppner R, Maehlmann J, Dirks M, Worthmann H, Tryc AB, Sandorski K, et
al. Neurological sequelae in adults after E coli O104: H4 infection-induced
hemolytic-uremic syndrome. Medicine (Baltimore). 2016;95(6):e2337.
10. Garg AX, Suri RS, Barrowman N, Rehman F, Matsell D, Rosas-Arellano MP, et
al. Long-term renal prognosis of diarrhea-associated hemolytic uremic
syndrome: a systematic review, meta-analysis, and meta-regression. JAMA.
2003;290(10):1360–70.
11. Phelps EA. Human emotion and memory: interactions of the amygdala and
hippocampal complex. Curr Opin Neurobiol. 2004;14(2):198–202.
12. Tsien JZ, Huerta PT, Tonegawa S. The essential role of hippocampal CA1
NMDA receptor-dependent synaptic plasticity in spatial memory. Cell. 1996;
87(7):1327–38.
13. Weissenborn K, Donnerstag F, Kielstein JT, Heeren M, Worthmann H, Hecker
H, et al. Neurologic manifestations of E coli infection-induced hemolytic-
uremic syndrome in adults. Neurology. 2012;79(14):1466–73.
14. Tironi-Farinati C, Loidl CF, Boccoli J, Parma Y, Fernandez-Miyakawa ME,
Goldstein J. Intracerebroventricular Shiga toxin 2 increases the expression of
its receptor globotriaosylceramide and causes dendritic abnormalities. J
Neuroimmunol. 2010;222(1–2):48–61.
15. Actis-Goretta L, Mackenzie GG, Oteiza PI, Fraga CG. Comparative study on
the antioxidant capacity of wines and other plant-derived beverages. Ann N
Y Acad Sci. 2002;957:279–83.
16. Tironi-Farinati C, Geoghegan PA, Cangelosi A, Pinto A, Loidl CF, Goldstein J.
A translational murine model of sub-lethal intoxication with Shiga toxin 2
reveals novel ultrastructural findings in the brain striatum. PLoS One. 2013;
8(1):e55812.
17. Pinto A, Jacobsen M, Geoghegan PA, Cangelosi A, Cejudo ML, Tironi-Farinati
C, et al. Dexamethasone rescues neurovascular unit integrity from cell
damage caused by systemic administration of Shiga toxin 2 and
lipopolysaccharide in mice motor cortex. PLoS One. 2013;8(7):e70020.
18. Testylier G, Lahrech H, Montigon O, Foquin A, Delacour C, Bernabe D, et al.
Cerebral edema induced in mice by a convulsive dose of soman. Evaluation
through diffusion-weighted magnetic resonance imaging and histology.
Toxicol Appl Pharmacol. 2007;220(2):125–37.
19. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial
intermediate filaments in differentiated astrocytes. J Neuroimmunol. 1985
Jun;8(4–6):203–14.
20. Mazzetti S, Frigerio S, Gelati M, Salmaggi A, Vitellaro-Zuccarello L.
Lycopersicon esculentum lectin: an effective and versatile endothelial
marker of normal and tumoral blood vessels in the central nervous system.
Eur J Histochem. 2004;48(4):423–8.
21. Gusel'nikova VV, Korzhevskiy DE. NeuN as a neuronal nuclear antigen and
neuron differentiation marker. Acta Nat. 2015;7(2):42–7.
22. Dent MA, Segura-Anaya E, Alva-Medina J, Aranda-Anzaldo A. NeuN/Fox-3 is
an intrinsic component of the neuronal nuclear matrix. FEBS Lett. 2010;
584(13):2767–71.
23. Vassall KA, Bamm VV, Harauz G. MyelStones: the executive roles of myelin
basic protein in myelin assembly and destabilization in multiple sclerosis.
Biochem J. 2015;472(1):17–32.
24. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S. Microglia-
specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol
Brain Res. 1998;57(1):1–9.
25. Lucero MS, Mirarchi F, Goldstein J, Silberstein C. Intraperitoneal
administration of Shiga toxin 2 induced neuronal alterations and reduced
the expression levels of aquaporin 1 and aquaporin 4 in rat brain. Microb
Pathog. 2012;53(2):87–94.
26. Nieuwdorp M, Meuwese MC, Vink H, Hoekstra JB, Kastelein JJ, Stroes ES. The
endothelial glycocalyx: a potential barrier between health and vascular
disease. Curr Opin Lipidol. 2005;16(5):507–11.
27. Ueno M. Mechanisms of the penetration of blood-borne substances into
the brain. Curr Neuropharmacol. 2009;7(2):142–9.
28. D'Alessio L, Pinto A, Cangelosi A, Geoghegan PA, Tironi-Farinati C, Brener GJ, et
al. Sub-lethal dose of Shiga toxin 2 from Enterohemorrhagic Escherichia coli
affects balance and cerebellar Cytoarchitecture. Front Microbiol. 2016;7:133.
29. Bahey NG, Abd Elaziz HO, Gadalla KK. Toxic effect of aflatoxin B1 and the
role of recovery on the rat cerebral cortex and hippocampus. Tissue Cell.
2015;47(6):559–66.
30. Sheth KJ, Swick HM, Haworth N. Neurological involvement in hemolytic-
uremic syndrome. Ann Neurol. 1986;19(1):90–3.
31. Gomez SA, Abrey-Recalde MJ, Panek CA, Ferrarotti NF, Repetto MG, Mejias
MP, et al. The oxidative stress induced in vivo by Shiga toxin-2 contributes
to the pathogenicity of haemolytic uraemic syndrome. Clin Exp Immunol.
2013;173(3):463–72.
32. Obata F, Tohyama K, Bonev AD, Kolling GL, Keepers TR, Gross LK, et al. Shiga
toxin 2 affects the central nervous system through receptor globotriaosylceramide
localized to neurons. J Infect Dis. 2008;198(9):1398–406.
33. Torres AG, Amaral MM, Bentancor L, Galli L, Goldstein J, Krüger A, Rojas-
Lopez M. Recent Advances in Shiga Toxin-Producing Escherichia coli
Research in Latin America. Microorganisms. 2018;6(4). https://doi.org/10.
3390/microorganisms6040100.
34. Brigotti M, Carnicelli D, Arfilli V, Tamassia N, Borsetti F, Fabbri E, et al.
Identification of TLR4 as the receptor that recognizes Shiga toxins in human
neutrophils. J Immunol. 2013;191(9):4748–58.
35. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector
cells in the normal and pathologic brain. Nat Neurosci. 2007;10(11):1387–94.
36. Goldstein J, Carden TR, Perez MJ, Taira CA, Hocht C, Gironacci MM.
Angiotensin-(1-7) protects from brain damage induced by Shiga toxin 2-
producing enterohemorrhagic Escherichia coli. Am J Physiol Regul Integr
Comp Physiol. 2016;311(6):R1173–R85.
37. Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the
mammalian central nervous system. Physiol Rev. 2001;81(2):871–927.
38. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J. Increased
production of interferon gamma and tumor necrosis factor precedes clinical
manifestation in multiple sclerosis: do cytokines trigger off exacerbations?
Acta Neurol Scand. 1988;78(4):318–23.
39. Sharief MK, Hentges R. Association between tumor necrosis factor-alpha
and disease progression in patients with multiple sclerosis. N Engl J Med.
1991 Aug 15;325(7):467–72.
40. Torre-Fuentes L, Moreno-Jiménez L, Pytel V, Matías-Guiu JA, Gómez-Pinedo
U, Matías-Guiu J. Experimental models of demyelination and remyelination.
Neurologia. 2017. https://doi.org/10.1016/j.nrl.2017.07.002.
Berdasco et al. Journal of Biomedical Science           (2019) 26:16 Page 12 of 12
